Lifecore to file for non-stick gel approval:
This article was originally published in Clinica
Lifecore Biomedical is to seek US approval next June for its Intergel solution for preventing post-operative adhesions. The company has completed a 200-patient trial of the ferric hyaluronate gel in female patients who have undergone open abdominal surgery. Additional cases will be treated pending FDA permission to close the study. Further studies are under way in patients who have undergone minimally invasive surgery.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.